Business Description
Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.48 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 3.09 | |||||
| Debt-to-EBITDA | -3.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.5 | |||||
| Beneish M-Score | -0.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.7 | |||||
| 3-Year EBITDA Growth Rate | 50.8 | |||||
| 3-Year EPS without NRI Growth Rate | 35.8 | |||||
| 3-Year FCF Growth Rate | 46.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.46 | |||||
| 9-Day RSI | 75.65 | |||||
| 14-Day RSI | 70.18 | |||||
| 6-1 Month Momentum % | -19.93 | |||||
| 12-1 Month Momentum % | -19.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | |||||
| Quick Ratio | 2.46 | |||||
| Cash Ratio | 2.22 | |||||
| Days Sales Outstanding | 34.53 | |||||
| Days Payable | 1459.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.07 | |||||
| Operating Margin % | -4.31 | |||||
| Net Margin % | 50.42 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 39.51 | |||||
| ROIC % | -22.03 | |||||
| ROC (Joel Greenblatt) % | -1613.23 | |||||
| ROCE % | -30.79 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.21 | |||||
| Price-to-Owner-Earnings | 2.68 | |||||
| PS Ratio | 1.37 | |||||
| PB Ratio | 7.08 | |||||
| Price-to-Tangible-Book | 7.08 | |||||
| EV-to-EBIT | -5.52 | |||||
| EV-to-Forward-EBIT | -19.44 | |||||
| EV-to-EBITDA | -5.57 | |||||
| EV-to-Forward-EBITDA | -20.09 | |||||
| EV-to-Revenue | 1.47 | |||||
| EV-to-Forward-Revenue | 1.87 | |||||
| EV-to-FCF | -33.09 | |||||
| Price-to-Median-PS-Value | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 8.14 | |||||
| Price-to-Net-Cash | 19.57 | |||||
| Earnings Yield (Greenblatt) % | -18.12 |
